SCHEMBL7606259

SCHEMBL7606259

CCN(Br)n1cnc2c1c(=O)n(C)c(=O)n2CC(C)C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 2/20 0.55
PDE1B Q01064 2/20 0.55
PDE1C Q14123 2/20 0.55
PDE4A P27815 10/20 0.50
PDE4B Q07343 10/20 0.50
PDE4C Q08493 10/20 0.50
PDE4D Q08499 10/20 0.50
ADORA2A P29274 7/20 0.50
ADORA2B P29275 5/20 0.50
PDE2A O00408 1/20 0.48
PDE5A O76074 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CFTR P13569 1/20 0.48
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
ADORA1 P30542 1/20 0.48
SCN1A P35498 1/20 0.48
PDE6C P51160 1/20 0.48
PDE3B Q13370 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1200300 0.80 ADORA2A (0.68) PDE1APDE1BPDE1CPDE4APDE4B
SCHEMBL4471527 0.80 PDE1A (0.67) PDE1APDE1BPDE1CPDE4APDE4B
SCHEMBL11033822 0.79 PDE1A (0.73) PDE1APDE1BPDE1CPDE4APDE4B
SCHEMBL11012550 0.78 PDE1A (0.64) PDE1APDE1BPDE1CPDE4APDE4B
SCHEMBL7089727 0.77 ADORA2B (0.68) PDE1APDE1BPDE1CPDE4APDE4B
SCHEMBL11004837 0.75 PDE4A (0.73) PDE1APDE1BPDE1CPDE4APDE4B
SCHEMBL11379486 0.74 PDE1A (0.54) PDE1APDE1BPDE1CPDE4APDE4B
SCHEMBL11386278 0.74 PDE1A (0.63) PDE1APDE1BPDE1CPDE4APDE4B
SCHEMBL27378735 0.73 PDE1A (0.65) PDE1APDE1BPDE1CPDE4APDE4B
SCHEMBL9853395 0.72 PDE4A (0.73) PDE1APDE1BPDE1CPDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020035117-A1 Theophylline and 3-isobutyl-1-methylxanthine based N-7 substituted derivatives displaying inhibitory activities on type five phosphodiesterase CHEN ING-JUN (TW) 2002-03-21 US claimed
US-20020035117-A1 Theophylline and 3-isobutyl-1-methylxanthine based N-7 substituted derivatives displaying inhibitory activities on type five phosphodiesterase CHEN ING-JUN (TW) 2002-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035117-A1 Theophylline and 3-isobutyl-1-methylxanthine based N-7 substituted derivatives displaying inhibitory activities on type five phosphodiesterase PDE3A, PDE3B, PDE5A PDE1A 78/4885PDE1B 83/4885PDE1C 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.